Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: Outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha

Cancer Immunology, Immunotherapy

Volumn 51, Issue 11-12, 2002, Pages 630-636

  Groenewegen, Gerard ^a   Bloem, Andries ^a   De Gast, Gijsbert C ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Division of Medical Oncology   (Netherlands)

Author keywords

Clinical trial; GM CSF; Immune activation; Melanoma; Sequential chemoimmunotherapy

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOMODULATION; MALE; MEDIATOR; MELANOMA; OUTPATIENT CARE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; SKIN METASTASIS; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TOXICITY; TREATMENT OUTCOME;

ADULT; AGED; DACARBAZINE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; T-LYMPHOCYTES;

EID: 0036451560     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0323-1     Document Type: Article

References (27)

1. Allouche M, Sahraoui Y, Augery-Bourget Y, Perrakis M, Jasmin C, Georgoulias V (1990) Interleukin-2 receptors. Leuk Res 14:699
2. Atzpodien J, Neuber K, Kamanabrou D, Fluck M, Brocker EB, Neumann C, Runger TM, Schuler G, von den DP, Muller I, Paul E, Patzelt T, Reitz M (2002) Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: Results of a prospective randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACI-MM). Br J Cancer 86:179
3. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635
4. Bour-Jordan H, Bluestone JA (2002) CD28 function: A balance of costimulatory and regulatory signals. J Clin Immunol 22:1
5. de Gast GC, Klumpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH (2000) Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res 6:1267
6. Ferrone S, Marincola FM (1995) Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487
7. Groenewegen G, de Gast GC (1999) GM-CSF can cause T cell activation: results of sequential chemo-immunotherapy. Eur J Cancer 35(3):S23
8. Hladik F, Tratkiewicz JA, Tilg H, Vogel W, Schwulera U, Kronke M, Aulitzky WE, Huber C (1994) Biologic activity of low dosage IL-2 treatment in vivo. Molecular assessment of cytokine network interaction. J Immunol 153:1449
9. Ho AD, Haas R, Wulf G, Knauf W, Ehrhardt R, Heilig B, Korbling M, Schulz G, Hunstein W (1990) Activation of lymphocytes induced by recombinant human granulocyte-macrophage colony-stimulating factor in patients with malignant lymphoma. Blood 75:203
10. Hodge S, Hodge G, Flower R, Han P (2000) Surface and intracellular interleukin-2 receptor expression on various resting and activated populations involved in cell-mediated immunity in human peripheral blood. Scand J Immunol 51:67
11. Huncharek M, Caubet JF, McGarry R (2001) Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: A meta-analysis of 3,273 patients from 20 randomized trials. Melanoma Res 11:75
12. Janik JE, Miller LL, Korn EL, Stevens D, Curti BD, Smith JW, Sznol M, Conlon KC, Sharfman W, Urba WJ, Gause BL, Longo DL (2001) A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. Blood 97:1942
13. Johnston SR, Constenla DO, Moore J, Atkinson H, A'Hern RP, Dadian G, Riches PG, Gore ME (1998) Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 77:1280
14. Keilholz U, Eggermont AM (2000) The emerging role of cytokines in the treatment of advanced melanoma. For the EO-RTC Melanoma Cooperative Group. Oncology 58:89
15. Keilholz U, Goey SH, Punt CJ, Proebstle TM, Salzmann R, Scheibenbogen C, Schadendorf D, Lienard D, Enk A, Dummer R, Hantich B, Geueke AM, Eggermont AM (1997) Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 15:2579
16. Kleinerman ES, Zwelling LA, Howser D, Barlock A, Young RC, Decker JM, Bull J, Muchmore AV (1980) Defective monocyte killing in patients with malignancies and restoration of function during chemotherapy. Lancet 2:1102
17. Lotze MT, Dallal RM, Kirkwood JM, Flickinger JC (2001) Cutaneous melanoma: Treatment of stage IV disease. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology, 6th Edition. Lippincott Williams & Raven, p 2048
18. Mulder NH, van der Graaf WT, Willemse PH, Koops HS, de Vries EG, Sleijfer DT (1994) Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma. Br J Cancer 70:681
19. + T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. J Infect Dis 178:1279
20. Ravaud A, Delaunay M, Chevreau C, Coulon V, Debled M, Bret-Dibat C, Courbon F, Gualde N, Nguyen BB (2001) Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: A randomized phase II trial. Br J Cancer 85:1467
21. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM (1999) Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17:968
22. Schrader AJ (2000) Combined chemoimmunotherapy in metastatic melanoma - Is there a need for the double? Anticancer Drugs 11:143
23. Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA, Soong SJ (2000) Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor [see comments]. J Clin Oncol 18:1614
24. Stasi R, Zinzani L, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Venditti A, Del Poeta G, Cantonetti M (1995) Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma. Eur J Haematol 54:9
25. Vaughan MM, Moore J, Riches PG, Johnston SR, A'Hern RP, Hill ME, Eisen T, Ayliffe MJ, Thomas JM, Gore ME (2000) GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): A phase I trial in melanoma. Ann Oncol 11:1183
26. Warren TL, Weiner GJ (2000) Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol 7:168
27. Witmer-Pack MD, Olivier W, Valinsky J, Schuler G, Steinman RM (1987) Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med 166:1484